199 related articles for article (PubMed ID: 35015210)
1. The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
Westhoff CL; Guo H; Wang Z; Hibshoosh H; Polaneczky M; Pike MC; Ha R
Breast Cancer Res Treat; 2022 Apr; 192(2):321-329. PubMed ID: 35015210
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
3. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
4. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS; Afrin S; Jones SI; Segars J
Endocr Rev; 2020 Oct; 41(5):. PubMed ID: 32365199
[TBL] [Abstract][Full Text] [Related]
5. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study.
Cameron ST; Berger C; Michie L; Klipping C; Gemzell-Danielsson K
Hum Reprod; 2015 Jul; 30(7):1566-72. PubMed ID: 25994664
[TBL] [Abstract][Full Text] [Related]
6. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma.
Hrgovic Z; Habek D; Cerkez Habek J; Hrgovic I; Jerkovic Gulin S; Gulin D
J Clin Pharm Ther; 2018 Feb; 43(1):121-123. PubMed ID: 28730656
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens.
Westhoff CL; Archer DF; Barnhart K; Darney P; Gilliam M; Jensen J; Nelson A; Teal S; Thomas M; Hu J; Brown J; Blithe DL
Contraception; 2022 Aug; 112():54-60. PubMed ID: 35430238
[TBL] [Abstract][Full Text] [Related]
9. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
10. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
11. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
12. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
13. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
14. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
15. Preoperative medical therapy before surgery for uterine fibroids.
Lethaby A; Puscasiu L; Vollenhoven B
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
[TBL] [Abstract][Full Text] [Related]
16. Selective progesterone receptor modulators.
Whitaker LH; Williams AR; Critchley HO
Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
[TBL] [Abstract][Full Text] [Related]
17. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
18. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
19. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
